Arbutus Biopharma (ABUS) Got Lower Wedbush Rating; Clarivest Asset Management Has Increased By $378,690 Its Rudolph Technologies (RTEC) Position

Among 2 analysts covering Arbutus Biopharma Corporation (ABUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arbutus Biopharma Corporation has $10.0 highest and $10 lowest target. $10’s average target is 90.48% above currents $5.25 stock price. Arbutus Biopharma Corporation had 3 analyst reports since January 4, 2018 according to SRatingsIntel. FBR Capital maintained Arbutus Biopharma Corporation (NASDAQ:ABUS) on Thursday, March 15 with “Buy” rating.

Clarivest Asset Management Llc increased Rudolph Technologies Inc (RTEC) stake by 7.38% reported in 2017Q3 SEC filing. Clarivest Asset Management Llc acquired 14,565 shares as Rudolph Technologies Inc (RTEC)’s stock rose 12.47%. The Clarivest Asset Management Llc holds 212,049 shares with $5.58M value, up from 197,484 last quarter. Rudolph Technologies Inc now has $948.25 million valuation. The stock increased 1.18% or $0.35 during the last trading session, reaching $30. About 436,493 shares traded or 92.91% up from the average. Rudolph Technologies, Inc. (NYSE:RTEC) has risen 79.97% since March 19, 2017 and is uptrending. It has outperformed by 63.27% the S&P500.

Among 7 analysts covering Rudolph Tech (NYSE:RTEC), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Rudolph Tech has $33.0 highest and $15.0 lowest target. $25.71’s average target is -14.30% below currents $30 stock price. Rudolph Tech had 16 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was upgraded by Dougherty & Company on Wednesday, April 19 to “Buy”. Credit Suisse downgraded the stock to “Underperform” rating in Tuesday, May 2 report. On Thursday, August 3 the stock rating was maintained by B. Riley & Co with “Buy”. Credit Suisse maintained Rudolph Technologies, Inc. (NYSE:RTEC) rating on Tuesday, October 31. Credit Suisse has “Underperform” rating and $24 target. On Friday, July 29 the stock rating was downgraded by Dougherty & Company to “Neutral”. DA Davidson maintained the stock with “Buy” rating in Tuesday, May 3 report. Stifel Nicolaus upgraded the stock to “Buy” rating in Friday, June 16 report. FBR Capital initiated Rudolph Technologies, Inc. (NYSE:RTEC) rating on Friday, February 2. FBR Capital has “Buy” rating and $32.0 target. The stock has “Neutral” rating by Credit Suisse on Tuesday, August 4. The company was downgraded on Wednesday, November 23 by Stifel Nicolaus.

Since February 14, 2018, it had 0 insider buys, and 4 selling transactions for $833,950 activity. Goodrich Michael F. had sold 2,500 shares worth $63,250 on Thursday, February 15. Shares for $151,260 were sold by Gardner Steven D. on Wednesday, February 14. Another trade for 18,000 shares valued at $468,180 was sold by ROTH STEVEN R.

Clarivest Asset Management Llc decreased Centerstate Bk Corp (NASDAQ:CSFL) stake by 33,900 shares to 141,700 valued at $3.80 million in 2017Q3. It also reduced Insight Enterprises Inc (NASDAQ:NSIT) stake by 51,385 shares and now owns 207,930 shares. Lam Research Corp (NASDAQ:LRCX) was reduced too.

Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.15, from 1.03 in 2017Q2. It worsened, as 18 investors sold RTEC shares while 60 reduced holdings. 21 funds opened positions while 59 raised stakes. 28.02 million shares or 1.14% more from 27.71 million shares in 2017Q2 were reported. Employees Retirement Systems Of Ohio reported 0% of its portfolio in Rudolph Technologies, Inc. (NYSE:RTEC). 34 are held by Howe & Rusling. Fny Managed Accounts Limited Liability Corp holds 572 shares or 0.02% of its portfolio. Gemmer Asset Management Limited Liability Com owns 0% invested in Rudolph Technologies, Inc. (NYSE:RTEC) for 202 shares. First Quadrant Limited Partnership Ca invested in 118,168 shares. Nationwide Fund holds 124,897 shares or 0.01% of its portfolio. Minnesota-based Thrivent Financial For Lutherans has invested 0.02% in Rudolph Technologies, Inc. (NYSE:RTEC). Old Mutual Glob Invsts (Uk) has invested 0.03% in Rudolph Technologies, Inc. (NYSE:RTEC). New York State Common Retirement Fund accumulated 0% or 67,866 shares. Barclays Public Lc invested in 0% or 1,415 shares. 20,000 were accumulated by Westwood Mngmt Corporation Il. Parametric Portfolio Associate Ltd Liability Corp stated it has 0% in Rudolph Technologies, Inc. (NYSE:RTEC). Legal General Group Inc Public Limited Co reported 0% of its portfolio in Rudolph Technologies, Inc. (NYSE:RTEC). Guggenheim Cap reported 58,464 shares or 0% of all its holdings. Thomson Horstmann And Bryant holds 0.58% or 160,763 shares.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $289.12 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The company??s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.